1	Running Title: Modern UNOS Data Reveals Septuagenarians have Inferior Heart Transplant
2	Survival
3	
4	Authors:
5	Manish Suryapalam <sup>1</sup> , Jay Kanaparthi <sup>1</sup> , Mohammed Kashem MD-PhD <sup>1</sup> , Huaqing Zhao PhD <sup>1</sup> ,
6	Yoshiya Toyoda MD-PhD <sup>1</sup>
7	****(ORCID# for each Author)****
8	
9	Institutions and Affiliations:
10	<sup>1</sup> Lewis Katz School of Medicine at Temple University, 3500 N Broad Street, Philadelphia, PA,
11	19140 and Division of Cardiovascular Surgery, Temple University Medical Center, 3401 N
12	Broad Street, Suite 301 Zone C, Philadelphia, PA, 19140
13	
14	Corresponding Author:
15	Manish Suryapalam, BS
16	1717 N 12 <sup>th</sup> Street, Philadelphia, PA, 19335
17	484-633-6497
18	manish.suryapalam@temple.edu
19	
20	Abbreviations: (only nontraditional abbreviations)
21	Word Count: 2038
22	
23	

2	Δ
4	т.

### Abstract

25	Background: While heart transplantation is increasingly performed in the United States for
26	elderly patients, survival outcomes have primarily been analyzed in single-center studies.
27	The few existing long-term studies have indicated no difference in HTx outcomes between
28	patients $\geq$ 70 years and 60-69 years age, but these studies only assessed to 5-years post-transplant
29	and included data from the 1980-90s, introducing significant variance due to poorer outcomes in
30	that era. We analyzed the UNOS database from 1987-2020, stratified by timeframe at 2000, to
31	derive a more representative comparison of modern HTx survival outcomes.
32	Methods: All UNOS HTx recipients over 18 years of age (n=66,186) were divided into 3
33	cohorts: 18-59, 60-69 and $\geq$ 70 years old. Demographic data as well as perioperative factors were
34	evaluated for significance using Chi-Squared and H-Tests as appropriate. Kaplan-Meier Curve
35	and cox regressions with log-rank tests were used to assess 5 through 10 year survival outcomes.
36	<b>Results:</b> 45,748 were 18-59 years old, 19,129 were 60-69 years old and 1,309 were $\geq$ 70 year old.
37	The distribution of most demographic and perioperative factors significantly differed between
38	cohorts. Pairwise survival analysis involving the 18-59 cohort always indicated significance.
39	While there was no significance between the two older cohorts in the earlier timeframe, there
40	was significance in the later timeframe from 6-10 years post-HTx (p<0.05). Cox regressions
41	confirmed results.
42	<b>Conclusions:</b> The results indicate that since 2000, recipients 60-69 years of age have better 6
43	through 10-year post-transplant survival than older recipients, a relationship previously obscured
44	by worse outcomes in early data.
45	

47

#### Introduction

48 Increasing age has long been considered a relative contraindication of heart transplant 49 (HTx).<sup>1</sup> However, as the prevalence of heart failure increases among older patients, the potential 50 role of heart transplant in this demographic demands further investigation.<sup>2</sup> The demand-supply 51 disparity for heart transplantations necessitates careful consideration of the criteria that comprise 52 adequate candidacy. Although heart transplantation has historically been limited for individuals 53 over the age of seventy, since 2006 the International Society for Heart and Lung Transplant 54 (ISHLT) issued guidelines have included greater candidacy consideration for these patients.<sup>3</sup> 55 While heart transplantation is increasingly performed in the United States for elderly patients, 56 survival outcome analysis has primarily been analyzed in single-center studies.<sup>4</sup> A single large-57 scale study has been published that analyzes HTx patients from the United Network for Organ 58 Sharing (UNOS) Database from 1987-2014, but this study only examined survival outcomes to 59 five years post-transplant, and did not determine the time at which significance in survival between the cohorts was reached.<sup>5</sup> A longer timeframe of analysis, incorporating new data from 60 61 2014-2020, could yield a more thorough understanding of survival outcomes in elderly patients. 62 This study compares the 5 to 10-year survival outcomes of patients  $\geq$ 70, 60-69, and 18-59 63 of age at the time of heart transplantation using data obtained from the UNOS Database from 64 1987-2020. The dataset was further split by timeframe into 1987-1999 and 2000-2020 for 65 additional analysis as we believed there was greater variance and differing survival outcomes in 66 earlier decades when compared to more recent years, which may mask patterns in modern 67 survival outcomes. 2000 was chosen as the cutoff for the modern timeframe because UNOS 68 launched its online database system UNet<sup>SM</sup> on October 25, 1999, just a few months prior. The

69 transition to UNet<sup>SM</sup> substantially increased the quality and quantity of organ donation and transplant event data available.<sup>6</sup> 70 71 Materials and Methods 72 Data Collection and Study Population 73 This study was a retrospective chart review performed using transplant data from the 74 UNOS Database, a comprehensive database containing information on all cardiac transplantation 75 patients in the United States. Temple University Institutional Review Board approved this study. 76 This study is in strict compliance with the 2014 ISHLT ethics statement. The study population 77 was comprised of 66,186 patients who underwent heart transplantation between October 1, 1987 78 and March 31, 2020. Patients were divided into three different age groups based on recipient age, 79 18-59, 60-69, and  $\geq$ 70 years old. Patients who underwent combined heart-lung transplants were 80 excluded from this analysis. 81 82 Outcomes 83 The primary outcome was mortality from 5 through 10-years post-transplant. Other 84 outcomes investigated included retransplant, hospital length of stay, graft rejection rates, renal 85 dysfunction (evaluated through dialysis), and ventricular assist device use. 86 87 Statistical analysis 88 All the data were analyzed using SPSS 26.0 (IBM Corp., Aramonk, NY). Many 89 demographic variables and baseline characteristics of heart transplant donors and recipients were 90 noted and expressed in Table 1 and Table 2 respectively as mean  $\pm$  standard deviation or median 91 as applicable. The nominal variables were evaluated for significance using Pearson's Chi-

92 Squared test. For continuous variables, a Shapiro-Wilk test was used to assess normality and a F 93 test was used to assess homogeneity of variance. In cases of non-normality, a Kruskal-Wallis H-94 test was performed evaluate significance in distribution. Otherwise, an ANOVA test was 95 performed. For further pairwise comparisons, a Mann-Whitney U-test was performed in cases of 96 non-normality. Otherwise, a two-sample t-test was used. If the F-test showed non-significance, 97 then the t-test was performed with an equal variance assumption. Otherwise, a two-sample t-test 98 with unequal variances was used. 99 Survival outcomes were assessed using Kaplan-Meier Survival Curves with log-rank tests 100 to assess significance at 5 through 10-years post-transplant by age cohort. Both overall 101 significance and pairwise significance was assessed (Table 3). Survival outcomes were assessed 102 over three timeframes. First, the entire time range was simultaneously analyzed. Second, only the 103 transplants that occurred between 1987 and December 31, 1999 were analyzed. Third, the 104 transplants that occurred between January 1, 2000 and 2020 were analyzed. 105 We also chose to perform regression modeling using stratified Cox proportional hazards 106 to evaluate the impact covariates on survival by age cohort. Survival outcomes at 5 through 10-107 years post-transplant in the modern timeframe were evaluated, with the hazard ratios and 108 confidence intervals for year 5 and 10 listed in Table 7. To avoid overfitting through excessive 109 covariates, we performed dimensionality reduction through the univariate shrinkage method, 110 where all covariates are initially assumed independent and then covariates that showed 111 significance (p < 0.05) or near significance (p < 0.10) were incorporated into an initial multivariate 112 Cox regression model. Near significant covariates were included due to the possibility that a 113 multiple interaction model could lead to a significant relationship. We then excluded variables 114 that showed nonsignifiance in the initial multivariate model to create a final Cox model. The Cox

115	regression model assumes that the effects of covariates on survival outcomes are not time
116	dependent. To test whether this assumption was met, a hierarchical regression strategy was used.
117	First, a cox regression was individually performed with the original set of covariates. Then, a
118	potential time dependent interaction with each covariate was modelled and the change in fit
119	between the original model and interaction model was evaluated using a likelihood ratio test for
120	statistical significance. If any covariate was found to be time-dependent, then the final survival
121	model included both the original covariate and its time-dependent interaction term. This
122	approach provides especially strong statistical evidence for derived conclusions on survival
123	outcomes.
124	Results:
125	Of the 66,186 patients analyzed, 45,748 (69.1%) were 18-60, 19,129 (28.9%) were 60-69,
126	and 1,309 (2.0%) were $\geq$ 70. The number of heart transplants performed annually has remained
127	relatively constant (or even slightly decreased when accounting for population growth), but the
128	proportion of heart transplants performed on elderly patients has continued to increase,
129	especially in recent years. Between the three cohorts, the demographic variables age, height,
130	weight, BMI, donor age, recipient ethnicity, recipient gender, cigarette use, HIV, EBV, donor
131	ethnicity, donor gender, and donor heavy alcohol consumption showed significance (Table 1).
132	The clinical variables ischemic time, previous dialysis, defibrillator, LVAD, RVAD, Other
133	VAD, and acute rejection were significant (Table 2).
134	In the oldest cohort, the median age was 71 and the oldest patient was 79. Across all three
135	age cohorts, the majority of patients were male and Caucasian. Far more patients were supported
136	with an LVAD than any other type of ventricular device before transplant, and a much larger

had a much higher graft incidence rate, although graft failure rates were more evenly distributedamongst the three cohorts.

140 Figures 1-3 indicate Kaplan-Meier Survival Curves to evaluate outcomes between the 141 three cohorts across the overall timeframe, 1987-1999, and 2000-2020 respectively. Table 3 142 highlights a survival breakdown by timeframe and Table 4 indicates significance by years post-143 transplant. As shown by Figure 1, the entire dataset showed overall significance when evaluated 144 for 5 through 10-year survival outcomes (p=0.000). This significance was driven almost entirely 145 by the improved survival outcomes of the 18-59 cohort, while pairwise comparisons revealed no 146 significance between the 60-69 and  $\geq$ 70 cohort in the overall timeframe. Survival at the 5-year 147 end point, was just above 75% and at the 10-year endpoint approximately 50% for all three 148 cohorts. However, further Kaplan-Meier split cohort analysis revealed a statistical difference in 149 the survival outcomes of modern heart transplant patients. For the cohort transplanted between 150 1987-1999 (Figure 2), there was similarly no significance between the 60-69 and  $\geq$ 70 cohort at 151 any endpoint analyzed, but in the 2000-2020 time range (Figure 3), there was near significance at 152 5 years post-transplant (p=0.095) and significance at every year thereafter with a 10 year 153 significance of p=0.003. Overall, modern survival outcomes are improved over older survival 154 outcomes, with an average survival of just under 60% in the modern group, but an average 155 survival under 50% in the older group over 10 years.

Figure 4 shows a cox regression model of the modern cohort, with many conventionally added covariates. The Cox proportional hazards regression model created to assess the impact of significant covariates on transplant type in the 2000-2020 timeframe showed overall significance in survival outcomes for all 5-10 years post-transplant and pairwise significance of the 60-69 and  $\geq$ 70 cohorts. The covariates that showed significance in a multivariate model included recipient

age, height, cigarette use, LOS, ischemic time, donor heavy alcohol use, dialysis, defibrillator,
ventilator, acute rejection, transfusion. The Cox model itself showed a statistically significant
improvement in evaluating survival outcomes when compared to its related Kaplan Meier curve
when evaluated by the Chi-Squared Omnibus Tests of Model Coefficients (p=0.000), and every
individual covariate except for height had a significant effect on survival outcomes. The hazard
ratios at 5 and 10-years post-transplant for each tested covariate are listed in Table 5, as well as
the significance and confidence interval of each covariate.

#### 168

#### Discussion

169 The results of this study, using a large patient data sample from the UNOS database to 170 evaluate long term survival outcomes, with data stratified by time, challenge the conclusions of 171 prior studies by demonstrating patients  $\geq$ 70 show inferior survival to patients 60-69 when 172 assessing the UNOS data over the last two decades rather than over the entirety of its existence. 173 Amongst studies that assessed hear transplant survival using the UNOS database, Weiss 174 et al. used data from 1999 to 2006 patients to demonstrate that patient over 60 showed acceptable 175 5-year survival but understandably inferior survival to patients 18-60 years of age.<sup>7</sup> Similarly, 176 George et al. studied the UNOS database from 2005-2011 to show that patient over the age of 70 had inferior survival to patients 18-70 years of age.<sup>8</sup> The last major UNOS study on the elderly 177 178 heart transplant recipient population done in 2015 by Cooper et al. who assessed the database 179 from 1987 to 2014 and showed that patients 70 years of age or older had similar outcomes to 180 recipients in their 60s. Our results using the UNOS data from 1987 to 2020 and 1987 to 2020 181 corroborate their results, showing significant overlap in survival outcomes of patients 60-69 and 182  $\geq$ 70 years of age. However, when we assessed the patient cohort from 2000-2020, eliminating 183 significant variance from poorer outcomes in all age groups from the 1980s and 1990s, we

identified a significant difference in survival between the patients age 60-69 and ≥70 years of
age.

186	The year 2018 marked the 50 <sup>th</sup> year anniversary of heart transplantation, and over those
187	decades we have seen remarkable improvement in technology and transplant technique. <sup>9</sup> Our
188	results clearly demonstrate improved survival in all age group in the 2000-2020 cohort compared
189	to the 1987-1999 cohort. Per UNOS, the 2019 1-year survival after lung transplantation is nearly
190	90%, and this may be partly attributed to advancements in organ procurement, <sup>10</sup> mechanical
191	circulatory support device usage, <sup>10</sup> improved organ rejection surveillance <sup>12</sup> , and newer
192	immunosuppressive agents. <sup>13</sup> However, amongst the overall improved survival rates of the
193	modern era, we have unmasked that survival in patients over 70 is inferior to those 60-69. Since
194	the Cooper et al. study in 2015, the number of patients who have undergone heart transplantation
195	has nearly doubled. As such, this study offers considerable evidence to reinvestigate the
196	hypothesis that patients in their seventies have comparable survival outcomes to younger patients
197	as well as further exploration into causes of this survival difference.
198	This study has several limitations. One is the substantial timeframe this study takes into
199	consideration. As noted earlier, there were several advancements in surgical technology and
200	technique between 1987 and 2020 as well as advances in mitigating complications that arise
201	post-transplant. While we mitigate some of these confounders by performing a two-cohort
202	analysis by time, there still remains many surgical improvements between 2000 and 2020. In
203	addition, the selection bias that was likely used in selecting older patients, which would have
204	contributed to increased survival. Furthermore, the analysis of survival outcomes did not
205	consider the rate of complications post-transplant between the two cohorts or any other related
206	"quality of life" assessment. Finally, this study was limited in accuracy by the data within the

207 UNOS database and does not account for variation in treatment of patients between various208 centers.

209 Our results demonstrate inferior survival in patients over the age of 70, challenging
210 results from the last large study of this kind and warranting further research into this survival
211 disparity.

212

## 213 Author Contributions:

214 Manish Suryapalam performed the analysis of the UNOS Database and wrote the preliminary

215 version of the manuscript with input from all authors. Jay Kanaparthi assisted in the statistical

216 analysis, verified results, and co-authored the preliminary manuscript. Abul Kashem conceived

217 of the presented idea, verified all results, and finalized the manuscript for submission. Huaqing

218 Zhao verified all analytical data and verified the suitability of various statistical tests. Norihisa

219 Shigemura and Yoshiya Toyoda provided critical feedback and helped shape the research,

analysis, and manuscript. All authors reviewed the manuscript prior to submission.

221

222

Financial Disclosure Statement: The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.

225

226

227

228

# 230 **Tables and Figures:**

# 231 Table 1: Demographic Characteristics


ruble 1. Demographie		Demographic Cha	racteristics			
Demographic Characteristics	Median	Mean	Standard Deviation	Significance		
	50.0	46.7	10.7			
Age (yrs)	63.0	63.7	2.7	0.000		
	71.0	71.4	1.6			
	175.0	173.5	10.0			
Height (cm)	175.3	174.3	9.3	0.000		
	175.3	174.6	11.7			
	79.4	80.3	17.7			
Weight (kg)	79.4	80.4	15.7	0.000		
	78.4	78.9	15.1			
	26.1	26.6	4.9			
BMI	26.0	26.4	4.3	0.000		
	25.4	25.7	3.9			
	28.0	30.3	11.6			
Donor Age (yrs)	31.0	35.8	13.3	0.000		
	35.0	32.5	12.4			
	Categorical Demographic Characteristics					
Demographic Characteristics	18-59	60-69	≥70	Significance		
Frequency	45748	19129	1309			
Recipient Ethnicity				0.000		
Caucasian	32376	15312	1095			
African American	8466	2217	123			
Latino	3264	1051	54			
Hispanic	3350	1072	54			
Recipient Gender				0.000		
Male	33706	15512	1150			
Recipient Cigarette Use	9061	6067	538	0.000		
Recipient Disease		I				
HIV	60	23	1	0.000		
EBV	20504	10496	903	0.000		
Donor Ethnicity		I		0.000		
Caucasian	32513	13343	868			
African American	6073	2511	178			

Latino	5969	2755	221	
Donor Gender				0.000
Male	32333	13471	878	
Donor Heavy				
Alcohol	3395	1993	216	0.000
Consumption				
Donor Cardiac	31	0	0	0.540
Death	51	7	0	0.540


232

233 Table 3: Clinical Characteristics


	Continu	ous Clinical Charac	eteristics	
Baseline Characteristics	Median	Mean	Standard Deviation	Significance
Length of Stay	14.00	20.6	25.3	
(days)	15.0	22.0	25.2	0.662
(days)	15.0	22.2	32.1	
Ischemic Time	3.0	3.0	1.0	
(hrs)	3.1	3.1	1.0	0.000
(111.5)	3.2	3.2	1.1	
	1.1	1.3	1.2	
Creatine	1.2	1.3	0.9	0.085
	1.1	1.3	1.3	
	3.7	3.6	0.7	
Serum Albumin	3.7	3.7	0.7	0.123
	3.7	3.7	0.7	
	Categori	ical Clinical Charac	eteristics	
Demographic Characteristics	18-59	60-69	≥70	Significance
Previous Dialysis	1678	584	20	0.000
Defibrillator	18528	10853	947	0.000
LVAD	6122	3161	213	0.000
RVAD	591	129	4	0.000
Other VAD	3013	1202	62	0.013
Ventilator	1139	400	28	0.008
Inhaled Nitrous Oxide	50	19	1	0.889
Acute Rejection	22306	11689	1076	0.000
Transfusion	8042	3386	173	0.000
Graft	29380	14187	1139	0.000
Graft Fail	23091	9331	496	0.000



# 234 Figure 1: Full Dataset, 10 years; Overall: p=0.000









239 240

Table 3: Survival Breakdown by Timeframe

Survival by					Years l	Post-Tra	nsplant				
Timeframe	Age Cat.	1	2	3	4	5	6	7	8	9	10
	18-59	0.881	0.842	0.810	0.780	0.747	0.713	0.678	0.641	0.604	0.568
1987-2020	60-69	0.859	0.824	0.794	0.763	0.729	0.688	0.643	0.596	0.552	0.503
	≥70	0.865	0.815	0.790	0.758	0.722	0.667	0.628	0.560	0.503	0.444
	18-59	0.850	0.809	0.776	0.743	0.706	0.670	0.630	0.859	0.551	0.512
1987-1999	60-69	0.814	0.772	0.737	0.702	0.667	0.622	0.574	0.525	0.483	0.437
	≥70	0.828	0.778	0.736	0.703	0.654	0.596	0.554	0.487	0.420	0.360
	18-59	0.901	0.864	0.834	0.805	0.776	0.746	0.717	0.686	0.652	0.622
2000-2020	60-69	0.877	0.844	0.817	0.788	0.755	0.718	0.676	0.634	0.588	0.541
	≥70	0.869	0.819	0.796	0.764	0.732	0.678	0.640	0.573	0.522	0.465


242 Table 4: Kaplan-Meier Significance by Years Post-Transplant

Age Cohort by	Years Post-Transplant Significance							
Timeframe	5-Years	6-Years	7-Years	8-Years	9-Years	10-Years		
1987-2020								
18-59 vs. 60-69	0.000	0.000	0.000	0.000	0.000	0.000		

18-59 vs. ≥70	0.050	0.006	0.004	0.000	0.000	0.000
60-69 vs ≥70	0.796	0.439	0.542	0.236	0.143	0.084
1987-1999						
18-59 vs. 60-69	0.000	0.000	0.000	0.000	0.000	0.000
18-59 vs. ≥70	0.203	0.091	0.087	0.027	0.006	0.002
60-69 vs ≥70	0.815	0.643	0.721	0.501	0.277	0.179
2000-2020						
18-59 vs. 60-69	0.000	0.000	0.000	0.000	0.000	0.000
18-59 vs. ≥70	0.000	0.000	0.000	0.000	0.000	0.000
60-69 vs ≥70	0.095	0.031	0.041	0.009	0.007	0.004

243

244 Figure 4: 2000-2020, 10 years- Cox Regression Model (p=0.000)



Time (years)



Covariate	5-Year Hazard Ratio	Confidence Interval		Sig.	10-Year Hazard Ratio	Confidence Interval		Sig.
Age Cohort								
60-69	Baseline			0.000	Baseline			0.000
18-59	0.773	0.725	0.825	0.000	0.761	0.720	0.803	0.000
≥70	1.167	1.021	1.334	0.023	1.171	1.046	1.310	0.006

Denerulle								
Donor Heavy								
Alcohol	D 1'			0.002	D 1'			
Yes	Baseline	0.055	1.000	0.093	Baseline	0.000	1.0.40	0.660
No	1.025	0.955	1.099	0.497	0.987	0.929	1.048	0.662
Unknown	1.180	1.016	1.370	0.030	0.109	0.977	1.258	0.109
Previous								
Dialysis								
Yes	Baseline			0.000	Baseline			0.000
No	0.633	0.579	0.692	0.000	0.683	0.631	0.740	0.000
Unknown	0.499	0.397	0.627	0.000	0.574	0.480	0.680	0.000
Previous								
Defibrillator								
Yes	Baseline			0.094	Baseline			0.006
No	1.050	0.998	1.104	0.062	1.069	1.025	1.115	0.002
Unknown	1.139	0.937	1.383	0.190	1.103	0.937	1.297	0.240
Ventilator								
Yes	Baseline			0.000	Baseline			0.000
No	0.489	0.435	0.549	0.000	0.610	0.548	0.680	0.000
Acute Rejection								
None	Baseline			0.000	Baseline			0.000
AR	0.897	0.743	1.083	0.258	0.903	0.772	1.056	0.201
CR/A	1.189	1.017	1.391	0.030	1.143	1.005	1.299	0.041
PNF	1.257	1.060	1.491	0.009	1.257	1.092	1.447	0.001
Transfusion								
Yes	Baseline			0.000	Baseline			0.000
No	0.845	0.802	0.891	0.000	0.896	0.856	0.937	0.000
Unknown	0.956	0.847	1.080	0.470	0.959	0.868	1.059	0.406
Cigarette Use	0.720	0.017	1.000	0.170	0.909	0.000	1.007	0.100
Yes	Baseline			0.000	Baseline			0.000
No	0.857	0.813	0.904	0.000	0.813	0.776	0.851	0.000
Unknown	1.212	1.073	1.370	0.000	1.162	1.055	1.279	0.002
Continuous	1,414	1.075	1.570	0.002	1.102	1.055	1.217	0.002
Variables								
Age	0.992	0.990	0.825	0.000	0.996	0.993	0.998	0.000
Height	0.992	1.021	1.334	0.000	0.990	0.993	0.996	0.000
LOS	1.005	1.021	1.006	0.000	1.005	1.004	1.005	0.000
Ischemic Time								
	1.108	1.086	1.132	0.000	1.075	1.057	1.094	0.000
Donor Age	1.011	1.009	1.013	0.000	1.010	1.009	1.012	0.000

## 251 **References**:

252	1.	Miller, L W. "Listing Criteria for Cardiac Transplantation: Results of an American
253		Society of Transplant Physicians-National Institutes of Health Conference."
254		Transplantation, U.S. National Library of Medicine, 15 Oct. 1998,
255		www.ncbi.nlm.nih.gov/pubmed/9798715. DOI: 10.1097/00007890-199810150-0003
256	2.	Savarese, G, and Lars HL. "Global Public Health Burden of Heart Failure." Cardiac
257		Failure Review, Radcliffe Cardiology, Apr. 2017,
258		www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/. DOI: 10.15420/cfr.2016:25:2
259	3.	Mehra, MR, et al. "The 2016 International Society for Heart Lung Transplantation
260		Listing Criteria for Heart Transplantation: A 10-Year Update." The Journal of Heart and
261		Lung Transplantation : the Official Publication of the International Society for Heart
262		Transplantation, U.S. National Library of Medicine, Jan. 2016,
263		www.ncbi.nlm.nih.gov/pubmed/26776864. DOI: 10.1016/j.healun.2015.10.023
264	4.	Yeom, SY, et al. "Heart Transplantation in the Elderly Patients: Midterm Results." The
265		Korean Journal of Thoracic and Cardiovascular Surgery, Korean Society for Thoracic
266		and Cardiovascular Surgery, Apr. 2013,
267		www.ncbi.nlm.nih.gov/pmc/articles/PMC3631784/. DOI: 10.5090/kjtcs.2013.46.2.111
268	5.	Cooper, LB, et al. "Cardiac Transplantation for Older Patients: Characteristics and
269		Outcomes in the Septuagenarian Population." The Journal of Heart and Lung
270		Transplantation : the Official Publication of the International Society for Heart
271		Transplantation, U.S. National Library of Medicine, Mar. 2016, DOI:
272		10.1016/j.healun.2015.10.028

273	6.	Gramham WK. UNet Goes Live. Organ procurement and Transplantation Network.
274		https://optn.transplant.hrsa.gov/news/unet-goes-live/. Published October 22, 1999.
275		Accessed April 7, 2021.
276	7.	Weiss ES, Nwakanma LU, Patel ND, Yuh DD. Outcomes in patients older than 60 years
277		of age undergoing orthotopic heart transplantation: an analysis of the UNOS database. $J$
278		Heart Lung Transplant 2008;27(2):184-91.
279	8.	George TJ, Kilic A, Beaty CA, Conte JV, Mandal K, Shah AS. Septuagenarians bridged
280		to heart transplantation with a ventricular assist device have outcomes similar to younger
281		patients. Ann Thorac Surg. 2013; 95(4):1251-61.
282	9.	Stehlik J, Kobashigawa J, Hunt SA, Reichenspurner H, Kirklin JK. Honoring 50 years of
283		clinical heart transplantation in Circulation: in-depth state-of-the-art-review. Circulation.
284		2018;137(1):71- 87
285	10.	Page A, Messer S, Large SR.Heart transplantation from donation after circulatory
286		determined death. Ann Cardiothorac Surg. 2018;7 (1):75-81
287	11.	Hanff TC, Harhay MO, Kimmel SE, et al. Trends in mechanical support use as a bridge
288		to adult heart transplantation under new allocation rules. JAMA Cardiol 2020;5(6):728-
289		729
290	12.	Dolan RS, Rahsepar AA, Blaisdell J, et al. Multiparametric cardiac magnetic resonance
291		imaging can detect acute cardiac allograft rejection after heart transplantation. JACC
292		Cardiovasc Imaging 2019;12(8):1632-1641
293	13.	Richmond ME, Zangwill SD, Kindel SJ, et al. Donor fraction cell-free DNA and
294		rejection in adult and pediatric heart transplantation. J Heart Lung Transplant
295		2020;39(5): 454-63.